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Summary.-The transplantable Guerin epithelioma in Wistar rats was used to test
the in vivo effectiveness of 1-(2-hydroxy-3-methoxypropyl)-2-methyl-4-nitroimid-
azole (P1) as a tumour-cell radiosensitizer after its oral administration at relatively
low doses. The radiosensitizing ability of P1 was compared with that of metronid-
azole. The results indicate that P1 is less toxic than metronidazole, and greater con-
centrations of P1 in blood and tumour tissues are obtained for the same adminis-
tered dose of the compounds. The radiosensitizing ability of P1, determined from
tumour-regression rates and local-control percentage at 130 days, was higher than
that of metronidazole.
UP TO NOW, the 4-iiitroimidlazoles as
radiosensitizers of hypoxic tumour cells
have been less well investigated than 2-
and 5-nitroimidazole compounds (Rauth
et al., 1978). Therefore, a closer investiga-
tion of this problem seems to be necessary
and the results may be of importance in
clinical radiotherapy. This paper de-
scribes preliminary results of experiments
with Compound P1 as a radiosensitizer
performed on a tumour system in vivo.
MATERIALS AND AIETHODS
Anti//al and tumour system. Inbred male
Wistar rats were used at an age of about
3 months. The solid Guerin epithelioma
(Guerin & Guerin, 1934) has been passaged
for many generations in this laboratory. This
tumour has a volume-doubling time during
the exponential period ofgrowAth in the range
of3-14-3 days, with a mean of 3-7 + 0-6 days.
From 2 weeks after transplantation, macro-
scopically visible metastases appeared fre-
quently, especially in the lymph nodes. The
mean survival time of the untreated tumour-
bearing animals was 32 + 3 days after trans-
plantation. The tumours were implanted s.c.
as fragments ( 2() m13 in SiZe) in the right
dorsal region of rats. Freely movable tumours
at a size of0 83-0 95 cm3. without perceptible
metastases and -without skin and muscle in-
filtration, were used for experiments, on the
average 2 wreeks after transplantation.
The compounds studied. Metronidazole was
obtained from "Polfa". The cornpound Pi
was synthesized by us (Suwvifiski et al., 1978).
Structures of the compounds and some of
their properties are shown in Table 1. Both
nitroimidazoles wvere given orally dissolved in
water (P1) or in suspension (mnetronidazole) at
doses of 0 15-0 6 g/kg body wt. P1 was ad-
ministered 60 min and metronidazole 90 min
before each irradiation. The concentration of
compounds in blood and tumour tissue wvas
estimated in the ethanol supernatants by
spectrophotometry at 314 nm (metronidazole)
and 302 nm (P1), according to the method
described by Urtasun et al. (1975).
Pi acute toxicity test.-The LD50 was
determined by giving animals (C3H mice and
Wistar rats) graded doses of compound P1
orally and observing deaths among the
animals at 2 and 30 days.
Evaluation of cytotoxicity on tumour.-Ex-
perimental groups of 10 tumour-bearing rats
with a mean tumour volume of 0 9 cm3 were
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t Witlh Chlinese Hamster- V79-379A cells in eitro.
given (except in the untreated group)
metroniidazole or P1 orally at a dose of 0 3
g/kg body wt. The aniinals received 10 doses
3 times weekly and the volume changes of
tumours were measured.
Irradiation procedure.-Local tumour irra-
diation was performed with a Stabilipan
X-ray machine operated at 200 kVp, 15 mA
(0.5 mmCu and 1P0 mm Al filtration) giving
a dose rate of about 10 Gy/min. Rats were
irradiated in a special metaplex holder
ensuring suitable restraint of animals, which
were breathing air during treatment, without
anaesthesia. The rest of the body was
shielded with 4mm-thick lead sheet. Frac-
tionated therapy was used, 4 Gy x 10=
40 Gy; 3 fractions per week.
Measurement of turmour response.-The
response to the various treatments was
determined using the parameter of tumour
regression and local control 130 days after the
start of treatment. The primary tumour was
considered cured (local control) wAhen it
could not be detected by palpation on the
130th day. The tumours were measured twice
a week by caliper in 3 mutually perpendicular
diameters and their volumes wAere calculated
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RESULTS AND I)ISCUSSION
The acute toxicity ofPi
We have established that after oral
administration of P1 the LD50/2d in C3H
mice was 54 g/kg body wt. Generally,
those mice which survived for 2 days also
survived for 30 days after P1 administra-
tion. These results, when compared with
the data ofBegg et al. (1974) for metronid-
azole in mice of the same line (LD50=
3-5 g/kg body wt), indicate that P1 is less
toxic than metronidazole. XVe have not
determined the LD50 for Wistar rats.
However, it has been established that no
death occurred within 30 days of oral
administration of P1 at a dose of 4-3 g/kg
body wt.
Lower toxicity of P1 in comparison with
metronidazole was also indicated by a
smaller decrease of body wt of rats after
10 doses of P1 given orally every second
day at a dose of 0 3 g/kg body wt. The
rats' body-wt losses were 12-0 + 6 g for the
P1 group and 46-0 + 9 g for the metronid-
azole group when the average untreated
rats weighed 348 + 7 g.
The above data, assayed in vivo, are in
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a good agreement with the conclusion that
the toxicities of nitroimidazoles for cells
in vitro grow less as their one-electron
reduction potential (E17) decreases
(Adams et al., 1976a).
Cytotoxicity ofcompounds studied
From the first day of administration
(especially P1) the tumour growth rate
decreased in comparison with that of the
untreated group. This trend continued to
the end of the experiment (after the 24th
day the rats were killed because of their
poor general state). On the 23rd day the
mean tumour volume in the metronidazole
group was 6 cm3 less and in the Pi group
10 cm3 less than in the untreated group
(51.3 + 6 3 cm3), but the differences were
not significant. It is very difficult to say
whether these reductions in tumour
volume are connected with a selective
cytotoxic action of Compound P1 on
hypoxic tumour cells.
The incidence of metastases is very high
for this tumour, comprising about 80% of
the untreated rats at the moment of their
death, i.e. 32 + 3 days after tumour trans-
plantation. Doubtless dissemination in
some rats may occur earlier than 2 weeks
after transplantation, i.e. before meta-
stases were macroscopically visible. It
seems that the drugs at the doses used do
not exert a direct cytotoxic effect on these
small foci and therefore on the incidence
of metastases. At the 24th day, the pro-
portions of rats with metastases in the
untreated, metronidazole and P1 groups
were 6/10, 5/10 and 6/10, respectively.
The concentration of compounds studied in
blood and tumour tissue
Mean concentrations of nitroimidazoles
in the blood and tumour tissue as a func-
tion of time after oral administration of
the compounds at various doses are shown
in Figs. I and 2.
P1 is characterized by a rapid accumu-
lation and it quickly reaches peak con-
centrations. After all 3 doses, the peak
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FIG. 1.-Levels of Compound P1 measured
spectroplhotometrically in the blood (closed
symbols) and wlhole-tumour extract (open
symbols) as a function of the time after
oral administration of 0-15 A, A; 0-3, *,
D- and 0 6 g/kg *, 0 body wt. The
vertical bars indicate the s.e. of 6-8
animals.
at 45-60 min and was 0 7, 1P0 and 1-9 mM
respectively.
In the tumour tissue at the same doses
the peak concentration appeared at similar
or slightly later times, and reached
75-88% of peak blood concentrations.
Wtith regard to metronidazole, after
doses of 0 3 and 0 6 g/kg body wt peak
concentration in the blood, 0 7 and 1-2 mm,
was reached at 60-120 min and at 90-120
min in the tumour (0.6 and 1-0 mmol/kg).
At both doses the tumour levels reached
83-86% of peak blood values. Thus, after
administration of equal doses (0 3 and 0-6
g/kg body wt) the concentration of P1 in
the blood and tumour tissue is -15 times
more than that of metronidazole; after
doses of 0 15 g/kg P1 and 0 3 g/kg
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FIcG. 2. Levels of metronidazole measured
spectroplhotometrically in the blood (closed
symbols) and wlhole-tumour extract (open
symbols) as a function of the time after
oral administration of 0-3 U, O and 0-6
0, 0 g/kg bodly wt. The vertical bars
indicate s.e. of 6 animals.
From the partition coefficients for PI
(0.44) and metronidazole (0.96) one could
expect that after oral administration of
the same dose of both compounds the
attainable concentration ofP1 in the blood
and in tumour should be the lower. The
results obtained show that the opposite is
true. This may be because Pi is more
soluble than metronidazole in water (as
well as in octanol). A number of other
factors (e.g. binding capacity with blood
proteins or acid-base features of the com-
pounds) may also influence the above
phenomenon. Rauth et al. (1978) have
reported a similar lack of correlation
between partition coefficients and plasma
concentrations for several 2-nitroimid-
azoles (P ranged from 0-14 to 1.92) in
experiments on C3H mice after i.p.
administration of the compounds.
Whatever factors determine the nitro-
imidazole concentration in tumour tissue,
its level is important, since the sensitizing
efficiency depends upon the local drug
concentration.
Fractionated irradiation and radiosensitizers
In the short pilot experiment the effect
of fractionated irradiation (10 x 4 Gy)
combined with graded doses of P1 (0.15,
0 3 and 0-6 g/kg body wt) on regression of
tumours (with a mean initial volume of
0 95 cm3) and regrowth at 45 days after
the start of treatment have been studied.
The shape of the regression curves (Fig. 3)
is similar for all 3 doses ofP1. The propor-
tions of rats without palpable tumour at
45 days (Table II) for these doses of Pi
were not significantly different.
On the basis of the data of the pilot
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FIG. 3.-Regression of tumours irradiated
with 10 x 4 Gy. Rats treated orally before
each irradiation with various doses of P1;
* *0-15, * 0-3and x x 06g/kg
body wt. Control 0 0. Mean tumour
volume expressed as a percentage of the
mean tumour volume of animals treated
with X-rays alone, as a function of time.
The arrows indicate the times oftreatment.
but effective quantities ofradiosensitizers,
nitroimidazoles (P1 or metronidazole) in
further experiments were administered in
doses of 0 3 g/kg body wt.
The effects of fractionated irradiation
combined with radiosensitizers at these
doses on tumour regression rates and local
control percentage in a representative ex-
periment are shown in Fig. 4(A, B) and in
Table III. The shapes of regression curves
during treatment were similar for both
nitroimidazoles. After treatment regrowth
of some of the tumours was seen in all
experimental groups, indicating incom-
__j
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TABLE 11. Effects offractionated irradia-
tion (10 x 4 Gy) contbined with graded
doses ofP1 on tumoutr absence at 45 days
No. Witlh WithiouLt
Expl of tuLmouir at, ttumotir at

























* Deatlh (dtue to metastases (4()- 45 daYs after start
of treatmenit).
Significance (X 2 test) of differences fioIn control
Xvalute:
tP>0 I.
§ P < 0*05.
plete killing of all tumour cells (Fig. 4(A)).
This regrowth was most rapid after X-ray
alone and slowest in the PI group, in
which the majority of tunmours decreased
further. The essential results of the ex-
periments are summarized in Table III.
The highest degree of local control at 130
days was 12/16 (750o of the tumours
irradiated) was obtained for Pl experi-
mental group, with the probability P=
0 075.
WVe have no information yet about the
proportion of hypoxic cells or on re-
oxygenationi during fractionated radio-
therapy of solid Guerin epitheliomas. On
the basis of macroscopic examination of
tumour structure (necrotic areas, network
of capillary vessels) it is assumed that the
proportion is significant and increases witlh
increasing tumour size. Thus we con-
sidered that improved survival of rats
0
Days after first irradiation
FiG. 4. Regression of ttumouri s irradiated
xvitl 10x4 Gy. Rats tIeated orally before
eacl irradiation wvith 0-3 g/kg of metron(l-
azole r Or 0-3 g/kg of P1 x x
Control O O. (A) AMean tumoutr voltume
as a funiction of time. (B) Alean ttumour
volume expressed as percenrtage of the
mean tumour volume of animals treatedl
with X-rays alone, as a functioni of time.
The arro'ws ind(licate the times of treatment.
without primary turnours was due to the
radiosensitizing effect of both drugs on
hypoxic cells of this tumniour.
In the experiment in vitro (Table 1) the
concentrations required to achieve a
sensitizer enhancement ratio (SER) of 1 6
for metronidazole and P1 were 4 and 8 mm
TABLE III. Late effects of fractionated irradiation conmbined with P1 or mnetronidazole
Experimental gropl) t
(I 6 iats in cachl gr'oulp)
Cointrol (irracliation only)





































* Deatli due to metastases (most frequenitly 40-50 days after the start of treatment).
Significance (X2 test) of dlifferences from control value: t P = 0-075; + P> 0 2.
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respectively. The in 'riro concentrations of
the compounds after doses of 0-3 g/kg
body wt were one order lower (0-62 and
0 92 mmol/kg) and it is not known what
SERs were achieved in tumour tissue. On
the basis of the data of Adams et al.
(1976b) it may be assumed, however, that
for nitroimidazoles with relatively lowN,
E17, as for metronidazole (E17= -486
mV') and Pi (El7= -564 mA) at concen-
trations within the range 01-1P0 mm (or
mmol/kg), the SER-determining factor
would be rather the compound tissue con-
centration than its E17. The better results
in the in vivo experiments with PI seeml to
confirm this assumption.
Irradiation combined with P1 or metroni-
idazole also prevents the formation of
metastases (Table III). A distinct correla-
tion exists between total and possibly
early eradication of primary tumour and
an absence of metastases. However, taking
into account the small numbers of animals
in the experimental groups, the data are
not statistically significant.
Regression of the tumour volume in in-
dividual experimental groups, as shown in
Fig. 4, indicates a correlation between
shrinkage during therapy and the prob-
ability of local control at 130 days (Table
III). This correlation is widely discussed
by Denekamp (1 977) and our results are
in good agreement, with her suggestions.
(ONCLUSIONS
I. Compound P1 shows a toxicity in
'tivo even lower than that of metronidazole
and may accumulate to a greater extent in
tuimour tissue after oral administration.
2. Compound P1 in small quantities, in
Combination with fractionated irradiationi
at relatively low doses, induces greater
local control thani metronidazole.
3. The results of experiments with an
aniimal tumour model resembling human
cancer permit the assumption that at
least some 4-nitroimidazoles might be
tilized as radiosensitizers in clinical trials.
4. 4-nitroimidazoles deserve further
comprehensive investigation.
X'e sbould like to tlhank Dr 1'. \ardman fot
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some tests of its properties, anIt Dr A. MIiclalowski
for hlis avlice on the preparationi of the manuscript
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